Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Phase I/II Trial of Glasdegib in Heavily Pre-Treated Patients with Primary or Secondary Myelofibrosis

Aaron T. Gerds, MDMS, Tetsuzo Tauchi, MD, Ellen K. Ritchie, MD, Michael W. Deininger, MD PhD, Catriona HM Jamieson, MD PhD, Ruben Mesa, MD FACP, Mark Lawrence Heaney, MD PhD, Norio Komatsu, MD PhD, Hironobu Minami, MD PhD, M. Naveed Shaik, PhD, Xiaoxi Zhang, PhD, Christine DiRienzo, PhD, Mirjana Zeremski, MD, Geoffrey Chan, MD, Moshe Talpaz, MD

Blood (2017) 130 (Supplement 1): 258.

https://doi.org/10.1182/blood.V130.Suppl_1.258.258

Published: 2017

Journal Articles

Synergistic Activity of Lysine Deacetylase Inhibitors and Microtubule-Targeting Agents in AML

James M Bogenberger, PhD, Nanna Hansen, M.S., Devora Delman, B.S., Lisa Sproat, MD MSW, Jeanne Palmer, MD, Ruben Mesa, MD FACP, Raoul Tibes, MD PhD

Blood (2016) 128 (22): 3948.

https://doi.org/10.1182/blood.V128.22.3948.3948

Published: 2016

Journal Articles

Myelodysplastic Syndromes and Acute Myelogenous Leukemia Resulting from Therapy for Autoimmune Disease, a Case-Control Cohort Study of 40,011 Patients

Natalie Ertz-Archambault, MD, Gretchen Taylor, MD, Heidi E. Kosiorek, MS, Amylou Constance Dueck, PhD, Janna Castro, Rob Marino, Susanne Gauthier, R.N., Katalin Kelemen, MD PhD, Laura E. Finn, MD, Lisa Sproat, MD MSW, Jeanne Palmer, MD, Ruben Mesa, MD FACP, Aref Al-Kali, MD, James M. Foran, MD, Raoul Tibes, MD PhD

Blood (2016) 128 (22): 296.

https://doi.org/10.1182/blood.V128.22.296.296

Published: 2016

Journal Articles

Impact of Myeloproliferative Neoplasms on Patients' Employment Status and Work Productivity in the United States: Results from the Living with MPN Patient Survey

Jingbo Yu, MHA, PhD, Shreekant Parasuraman, BPharm, PhD, Dilan Paranagama, PhD, Ahmad Naim, MD, David Dubinski, MBA, Andrew Bai, MS, Ruben Mesa, MD FACP

Blood (2016) 128 (22): 4256.

https://doi.org/10.1182/blood.V128.22.4256.4256

Published: 2016

Journal Articles

A Two-Part Study of Givinostat in Patients with Polycythemia Vera: Maximum Tolerated Dose Definition and Preliminary Efficacy Results

Guido Finazzi, MD, Bruno Martino, MD, Antonio Pezzuto, Andrzej Hellmann, MD, Mary Frances McMullin, MD, Richard Noble, MD, Nikolas von Bubnoff, Prof., PhD, Nathalie Cambier, MD, Jean-Pierre Marolleau, MD PhD, Marco Ruggeri, MD, Alessandro M. Vannucchi, MD PhD, Ruben Mesa, MD FACP, Raoul Tibes, MD PhD, Paolo Bettica, MD PhD, Silvia DI Tollo, DHSC, BSc, Alessandro Rambaldi, MD

Blood (2016) 128 (22): 4261.

https://doi.org/10.1182/blood.V128.22.4261.4261

Published: 2016

Journal Articles

Examining the Clinical Features and Underlying Cardiovascular Risk Among Patients with Polycythemia Vera in the REVEAL Study

Brady L. Stein, MD, Ahmad Naim, MD, Michael R. Grunwald, MD, Alison R. Moliterno, MD, Stephen T. Oh, MD PhD, Dilan Paranagama, PhD, Joseph A. Cordaro, PharmD, MBA, Hao Sun, MS, Shreekant Parasuraman, BPharm, PhD, Ralph V. Boccia, Ruben Mesa, MD FACP

Blood (2016) 128 (22): 1934.

https://doi.org/10.1182/blood.V128.22.1934.1934

Published: 2016

NARROW

Phase I/II Trial of Glasdegib in Heavily Pre-Treated Patients with Primary or Secondary Myelofibrosis

Synergistic Activity of Lysine Deacetylase Inhibitors and Microtubule-Targeting Agents in AML

Myelodysplastic Syndromes and Acute Myelogenous Leukemia Resulting from Therapy for Autoimmune Disease, a Case-Control Cohort Study of 40,011 Patients

Impact of Myeloproliferative Neoplasms on Patients' Employment Status and Work Productivity in the United States: Results from the Living with MPN Patient Survey

A Two-Part Study of Givinostat in Patients with Polycythemia Vera: Maximum Tolerated Dose Definition and Preliminary Efficacy Results

Examining the Clinical Features and Underlying Cardiovascular Risk Among Patients with Polycythemia Vera in the REVEAL Study

Email alerts

ASH Publications

American Society of Hematology

Phase I/II Trial of Glasdegib in Heavily Pre-Treated Patients with Primary or Secondary Myelofibrosis

Synergistic Activity of Lysine Deacetylase Inhibitors and Microtubule-Targeting Agents in AML

Myelodysplastic Syndromes and Acute Myelogenous Leukemia Resulting from Therapy for Autoimmune Disease, a Case-Control Cohort Study of 40,011 Patients

Impact of Myeloproliferative Neoplasms on Patients' Employment Status and Work Productivity in the United States: Results from the Living with MPN Patient Survey

A Two-Part Study of Givinostat in Patients with Polycythemia Vera: Maximum Tolerated Dose Definition and Preliminary Efficacy Results

Examining the Clinical Features and Underlying Cardiovascular Risk Among Patients with Polycythemia Vera in the REVEAL Study

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only